Aaron Mochizuki

Employment

• Cincinnati Children's Hospital Medical Center Pediatric neuro-oncologist
  2021 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (39)

• Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma
  Nature Medicine 2026 DOI: 10.1038/s41591-026-04646-6
  +Save
• Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype-specific phenotypes
  Neuro-Oncology 2026 DOI: 10.1093/neuonc/noag228
  +Save
• Discordant neoplasms in monozygotic twins with a germline RECQL5 variant
  Cancer Genetics 2026 DOI: 10.1016/j.cancergen.2026.07.006
  +Save
• A frontal lobe mass in a 6‐year‐old girl
  Brain Pathology 2026 DOI: 10.1111/bpa.70132
  +Save
• MEK Inhibitor-Induced Dropped Head Syndrome in Pediatrics
  Neuro-Oncology Pediatric 2026 DOI: 10.1093/neuped/wuag024
  +Save
• Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Pediatric Patients with Refractory or Recurrent High-Grade Gliomas: A Report of the Pediatric Brain Tumor Consortium
  Onco 2025 DOI: 10.3390/onco5010001
  +Save
• IMMU-17. A PHASE I STUDY OF INTRATUMORAL/PERITUMORAL HERPES SIMPLEX VIRUS-1 MUTANT HSV1716 IN PATIENTS WITH REFRACTORY OF RECURRENT HIGH-GRADE GLIOMAS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
  Neuro-Oncology 2024 DOI: 10.1093/neuonc/noae064.388
  +Save
• MDB-45. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA
  Neuro-Oncology 2024 DOI: 10.1093/neuonc/noae064.494
  +Save
• Germline <scp>PTCH1</scp>: <scp>c.361_362insAlu</scp> alteration identified by comprehensive exome and <scp>RNA</scp> sequencing in a patient with <scp>Gorlin</scp> syndrome
  American Journal of Medical Genetics Part A 2024 DOI: 10.1002/ajmg.a.63788
  +Save
• 14q22.3 duplication including OTX2 in a girl with medulloblastoma: A case report with literature review
  American Journal of Medical Genetics Part A 2024 DOI: 10.1002/ajmg.a.63604
  +Save
• Pediatric Embryonal Tumors
  Neuro-Oncology Compendium for the Boards and Clinical Practice 2023 DOI: 10.1093/med/9780197573778.003.0016
  +Save
• CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS
  Neuro-Oncology 2023 DOI: 10.1093/neuonc/noad073.044
  +Save
• MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA
  Neuro-Oncology 2023 DOI: 10.1093/neuonc/noad073.250
  +Save
• GABAergic neuron-to-glioma synapses in diffuse midline gliomas
  2022 DOI: 10.1101/2022.11.08.515720
  +Save
• QOL-23. Expanded protocols for hearing loss related cisplatin-based therapy in childhood cancer patients.
  Neuro-Oncology 2022 DOI: 10.1093/neuonc/noac079.506
  +Save
• GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
  Robbie G. Majzner, Sneha Ramakrishna, Kristen W. Yeom +44 more
  Nature 2022 DOI: 10.1038/s41586-022-04489-4
  +Save
• Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
  Nature Communications 2021 DOI: 10.1038/s41467-021-26940-2
  +Save
• Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
  2021 DOI: 10.21203/rs.3.rs-793187/v1
  +Save
• EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG
  Neuro-oncology 2021
  +Save
• OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
  Neuro-oncology 2021
  +Save